The first result, published in 2015, from the EMPA-REG OUTCOME trial, whose primary focus was on the use of empagliflozin in reducing major adverse cardiovascular events (MACE) defined as non-fatal MI, stroke, and CV death in diabetics heralded this evolutionary investigation into SGLT2 inhibitors [4]. Here, SLC5A2 is linked to stroke disorder.